Literature DB >> 9886295

Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding.

D Y Chirgadze1, J P Hepple, H Zhou, R A Byrd, T L Blundell, E Gherardi.   

Abstract

Although ligand-induced receptor dimerization is a common prerequisite for receptor activation, the mode by which different growth factors bind their receptors and cause them to dimerize varies considerably. Here we report the crystal structure at 2.5 A resolution of NK1, a receptor-binding fragment and a natural splice variant of hepatocyte growth factor/scatter factor (HGF/SF). NK1 assembles as a homodimer in the asymmetric unit, revealing a novel mode of growth factor dimerization produced by close packing of the N domain of one subunit and the kringle domain of the other, thus bringing the two linkers in close proximity. The structure suggests the presence of a binding site for heparan sulfate chains and a mechanism by which the NK1 dimer may engage two receptor molecules through clusters of amino acids located on each protomer and on opposite surfaces of the homodimer. We also report that short (14-mer) heparin fragments effectively dimerize NK1 in solution, implying that heparan sulfate chains may stabilize the NK1 dimer. These results provide a basis for the agonistic activity of NK1 and have implications for the mechanism of receptor binding of HGF/SF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886295     DOI: 10.1038/4947

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  38 in total

Review 1.  Heparan sulfate: growth control with a restricted sequence menu.

Authors:  J T Gallagher
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Authors:  Sonya B Sonnenberg; Aboli A Rane; Cassie J Liu; Nikhil Rao; Gillie Agmon; Sophia Suarez; Raymond Wang; Adam Munoz; Vaibhav Bajaj; Shirley Zhang; Rebecca Braden; Pamela J Schup-Magoffin; Oi Ling Kwan; Anthony N DeMaria; Jennifer R Cochran; Karen L Christman
Journal:  Biomaterials       Date:  2015-01-13       Impact factor: 12.479

4.  An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Authors:  Cassie J Liu; Douglas S Jones; Ping-Chuan Tsai; Abhishek Venkataramana; Jennifer R Cochran
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

5.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

6.  Preparation of heparin/heparan sulfate oligosaccharides with internal N-unsubstituted glucosamine residues for functional studies.

Authors:  Zheng Wei; Jon Andrew Deakin; Bärbel Sabine Blaum; Dušan Uhrín; John Thomas Gallagher; Malcolm Lyon
Journal:  Glycoconj J       Date:  2011-09-21       Impact factor: 2.916

7.  Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.

Authors:  T Otsuka; J Jakubczak; W Vieira; D P Bottaro; D Breckenridge; W J Larochelle; G Merlino
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor.

Authors:  Toby Passioura; Hiroki Sato; Katsuya Sakai; Kenichiro Ito; Hiroki Furuhashi; Masataka Umitsu; Junichi Takagi; Yukinari Kato; Hidefumi Mukai; Shota Warashina; Maki Zouda; Yasuyoshi Watanabe; Seiji Yano; Mikihiro Shibata; Hiroaki Suga; Kunio Matsumoto
Journal:  Nat Chem Biol       Date:  2019-05-17       Impact factor: 15.040

9.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

10.  Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.

Authors:  Julie M Schultz; Shaheen N Khan; Zubair M Ahmed; Saima Riazuddin; Ali M Waryah; Dhananjay Chhatre; Matthew F Starost; Barbara Ploplis; Stephanie Buckley; David Velásquez; Madhulika Kabra; Kwanghyuk Lee; Muhammad J Hassan; Ghazanfar Ali; Muhammad Ansar; Manju Ghosh; Edward R Wilcox; Wasim Ahmad; Glenn Merlino; Suzanne M Leal; Sheikh Riazuddin; Thomas B Friedman; Robert J Morell
Journal:  Am J Hum Genet       Date:  2009-07-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.